DLTs in phase 1b (safety analysis set)
| Investigation . | Phase 1b dose-escalation phase, n (%) . | Phase 1b dose expansion phase, n (%) . | . | ||
|---|---|---|---|---|---|
| Sonidegib 400 mg + ruxolitinib 10 mg (n = 8) . | Sonidegib 400 mg + ruxolitinib 15 mg (n = 10) . | Sonidegib 400 mg + ruxolitinib 20 mg (n = 5) . | Sonidegib 400 mg + ruxolitinib 20 mg (n = 27) . | All patients (N = 50), n (%) . | |
| Increased blood creatine phosphokinase | 0 (0.0) | 2 (20.0) | 0 (0.0) | 1 (3.7) | 3 (6.0) |
| Investigation . | Phase 1b dose-escalation phase, n (%) . | Phase 1b dose expansion phase, n (%) . | . | ||
|---|---|---|---|---|---|
| Sonidegib 400 mg + ruxolitinib 10 mg (n = 8) . | Sonidegib 400 mg + ruxolitinib 15 mg (n = 10) . | Sonidegib 400 mg + ruxolitinib 20 mg (n = 5) . | Sonidegib 400 mg + ruxolitinib 20 mg (n = 27) . | All patients (N = 50), n (%) . | |
| Increased blood creatine phosphokinase | 0 (0.0) | 2 (20.0) | 0 (0.0) | 1 (3.7) | 3 (6.0) |